Little O O
known O O
molecular O O
carcinogenesis O O
oral O O
squamous O O
cell O O
carcinoma O O
( O O
OSCC O O
) O O
young O O
adult O O
patients O O
. O O

The O O
aim O O
study O O
investigate O O
detailed O O
TP53 O O
mutation O O
human B-virus B-virus
papilloma I-virus I-virus
virus E-virus E-virus
( O O
HPV B-virus B-virus
) O O
status O O
OSCC O O
patients O O
, O O
younger O O
45 O O
years O O
. O O

The O O
mutational O O
makeup O O
HPV-positive B-virus B-virus
HPV-negative B-virus B-virus
HNSCC O O
differs O O
significantly O O
, O O
including O O
targetable O O
genes O O
. O O

HNSCC O O
harbors O O
multiple O O
therapeutically O O
important O O
genetic O O
aberrations O O
, O O
including O O
frequent O O
aberrations O O
FGFR O O
PI3K O O
pathway O O
genes O O
. O O

See O O
related O O
commentary O O
Krigsfeld O O
Chung O O
, O O
p. O O
495 O O
. O O

Registry O O
data O O
East O O
Germany O O
used O O
determine O O
incidence O O
trends O O
1998 O O
2011 O O
. O O

Data O O
patients O O
treated O O
Charité O O
University O O
Medicine O O
Berlin O O
2004 O O
2013 O O
( O O
cohort O O
1 O O
, O O
N=436 O O
) O O
used O O
estimation O O
trends O O
HPV B-virus B-virus
prevalence O O
, O O
smoking O O
survival O O
. O O

HPV B-virus B-virus
prevalence O O
prospectively O O
confirmed O O
cohort O O
2 O O
( O O
N=213 O O
) O O
comprising O O
primary O O
HNSCC O O
cases O O
Charité O O
2013 O O
. O O

Fine O O
needle O O
aspirates O O
( O O
FNA O O
) O O
cervical O O
lymph O O
nodes O O
pre-operatively O O
obtained O O
patients O O
suspected O O
HNSCCs O O
evaluated O O
presence O O
HPV B-virus B-virus
using O O
HC-2 O O
assay O O
. O O

HPV B-virus B-virus
analysis O O
performed O O
corresponding O O
resected O O
tissue O O
specimens O O
using O O
p16 O O
immunohistochemistry O O
( O O
IHC O O
) O O
HR-HPV B-virus B-virus
situ O O
hybridization O O
( O O
ISH O O
) O O
. O O

A O O
cost O O
analysis O O
performed O O
using O O
Center O O
Medicare O O
& O O
Medicaid O O
Services O O
. O O

Strong O O
diffuse O O
p16 O O
immunoreactivity O O
found O O
7 O O
40 O O
cases O O
( O O
17.5 O O
% O O
) O O
. O O

In O O
situ O O
hybridization O O
showed O O
diffuse O O
episomal O B-virus
signal O O
samples O O
. O O

However O O
, O O
PCR O O
could O O
reliably O O
detect O O
presence O O
HPV B-virus B-virus
genes O O
. O O

Furthermore O O
, O O
p16-expressing O O
epithelial O O
cells O O
mostly O O
negative O O
proliferation O O
marker O O
Ki-67 O O
. O O

The O O
overall O O
mutational O O
burden O O
HPV-negative B-virus B-virus
HPV-positive B-virus B-virus
HNSCC O O
similar O O
average O O
15.2 O O
versus O O
14.4 O O
somatic O O
exonic O O
mutations O O
targeted O O
cancer-associated O O
genes O O
. O O

HPV-negative B-virus B-virus
tumors O O
showed O O
mutational O O
spectrum O O
concordant O O
published O O
lung O O
squamous O O
cell O O
carcinoma O O
analyses O O
enrichment O O
mutations O O
TP53 O O
, O O
CDKN2A O O
, O O
MLL2 O B-virus
, O O
CUL3 O B-virus
, O O
NSD1 O O
, O O
PIK3CA O O
, O O
NOTCH O O
genes O O
. O O

HPV-positive B-virus B-virus
tumors O O
showed O O
unique O O
mutations O O
DDX3X O B-virus
, O O
FGFR2/3 O B-virus
aberrations O O
PIK3CA O O
, O O
KRAS O O
, O O
MLL2/3 O B-virus
, O O
NOTCH1 O O
enriched O O
HPV-positive B-virus B-virus
tumors O O
. O O

Currently O O
targetable O O
genomic O O
alterations O O
identified O O
FGFR1 O O
, O O
DDR2 O O
, O O
EGFR O O
, O O
FGFR2/3 O O
, O O
EPHA2 O O
, O O
PIK3CA O O
. O O

EGFR O O
, O O
CCND1 O O
, O O
FGFR1 O O
amplifications O O
occurred O O
HPV-negative B-virus B-virus
tumors O O
, O O
whereas O O
17.6 O O
% O O
HPV-positive B-virus B-virus
tumors O O
harbored O O
mutations O O
fibroblast O O
growth O O
factor O O
receptor O O
genes O O
( O O
FGFR2/3 O O
) O O
, O O
including O O
six O O
recurrent O O
FGFR3 O O
S249C O O
mutations O O
. O O

HPV-positive B-virus B-virus
tumors O O
showed O O
5.8 O O
% O O
incidence O O
KRAS O O
mutations O O
, O O
DNA-repair O O
gene O O
aberrations O O
, O O
including O O
7.8 O O
% O O
BRCA1/2 O O
mutations O O
, O O
identified O O
. O O

Of O O
107 O O
cases O O
study O O
, O O
40 O O
per O O
cent O O
( O O
n O O
= O O
41 O O
) O O
human B-virus B-virus
papilloma I-virus I-virus
virus E-virus E-virus
positive O O
. O O

The O O
positive O O
negative O O
predictive O O
values O O
p16 O O
immunohistochemistry O O
human B-virus B-virus
papilloma I-virus I-virus
virus E-virus E-virus
status O O
57 O O
per O O
cent O O
100 O O
per O O
cent O O
, O O
respectively O O
. O O

At O O
mean O O
follow O O
59.5 O O
months O O
, O O
5-year O O
overall O O
disease-specific O O
survival O O
estimates O O
78 O O
per O O
cent O O
69 O O
per O O
cent O O
, O O
respectively O O
. O O

Human B-virus B-virus
papilloma I-virus I-virus
virus E-virus E-virus
status O O
( O O
p O O
= O O
0.014 O O
) O O
, O O
smoking O O
status O O
( O O
p O O
= O O
0.021 O O
) O O
tumour O O
stage O O
( O O
p O O
= O O
0.03 O O
) O O
significant O O
prognostic O O
indicators O O
. O O

A O O
transversal O O
prospective O O
study O O
conducted O O
analyze O O
seasonality O O
CRS O O
using O O
real-time O O
polymerase O O
chain O O
reaction O O
detect O O
respiratory B-virus B-virus
virus E-virus E-virus
genomes O O
secretions O O
tissue O O
samples O O
patients O O
CRS O O
without O O
nasal O O
polyps O O
. O O

In O O
addition O O
tobacco O O
alcohol O O
consumption O O
, O O
two O O
main O O
risk O O
factors O O
oral O O
squamous O O
cell O O
carcinoma O O
( O O
OSCC O O
) O O
, O O
recent O O
studies O O
revealed O O
infections O O
human B-virus B-virus
papilloma I-virus I-virus
virus E-virus E-virus
( O O
HPV B-virus B-virus
) O O
additional O O
risk O O
factor O O
OSCC O O
development O O
. O O

In O O
field O O
head O O
neck O O
malignancies O O
, O O
prevalence O O
HPV B-virus B-virus
infections O O
oropharyngeal O O
cancer O O
( O O
OC O O
) O O
ranges O O
different O O
studies O O
84 O O
% O O
. O O

While O O
HPV B-virus B-virus
infection O O
discussed O O
independent O O
risk O O
factor O O
region O O
, O O
distinguished O O
role O O
carcinogenesis O O
tumours O O
localized O O
oral O O
cavity O O
remains O O
still O O
uncertain O O
. O O

In O O
study O O
, O O
analysed O O
HPV B-virus B-virus
status O O
88 O O
consecutive O O
patients O O
OSCCs O O
localized O O
anterior O O
palatoglossal O O
arch O O
treated O O
Department O O
Oral O O
Maxillofacial O O
Surgery O O
University O O
Medical O O
Center O O
Mainz O O
. O O

The O O
HPV B-virus B-virus
status O O
analysis O O
performed O O
using O O
DNA-PCR O O
immunostaining O O
p16 O O
protein O O
. O O

The O O
prevalence O O
HPV-positive O B-virus
OSCCs O O
6 O O
% O O
( O O
5 O O
patients O O
) O O
. O O

In O O
3 O O
patients O O
HPV B-virus B-virus
subtypes O O
16/18 E-virus O
found O O
. O O

No O O
significant O O
differences O O
HPV B-virus B-virus
positive O O
negative O O
patients O O
regarding O O
age O O
, O O
gender O O
, O O
smoking O O
alcohol O O
consumption O O
, O O
localization O O
TNM O O
level O O
could O O
detected O O
. O O

Contrary O O
studies O O
focussing O O
cancers O O
lingual O O
palatine O O
tonsil O O
, O O
prevalence O O
HPV B-virus B-virus
infections O O
much O O
lower O O
oral O O
cavity O O
. O O

Therefore O O
HPV B-virus B-virus
infection O O
might O O
play O O
less O O
important O O
role O O
oral O O
carcinogenesis O O
. O O

Patients O O
HPV-associated B-virus B-virus
head O O
neck O O
second O O
primary O O
tumors O O
3 O O
centers O O
identified O O
. O O

HPV B-virus B-virus
infection O O
evaluated O O
using O O
p16 O O
immunohistochemistry O O
( O O
IHC O O
) O O
, O O
high-risk O B-virus
HPV B-virus E-virus
DNA O O
situ O O
hybridization O O
( O O
ISH O O
) O O
, O O
HPV B-virus B-virus
genotyping O O
DNA O O
polymerase O O
chain O O
reaction O O
( O O
PCR O O
) O O
enzyme O O
immunoassay O O
( O O
EIA O O
) O O
. O O

The O O
CMCSCC-1 O O
cell O O
line O O
isolated O O
primary O O
oral O O
tongue O O
tumor O O
specimen O O
female O O
patient O O
. O O

Tumor O O
cells O O
evaluated O O
biomarkers O O
expression O O
Western O O
blots O O
, O O
reverse O O
transcriptase-polymerase O O
chain O O
reaction O O
( O O
RT-PCR O O
) O O
, O O
fluorescence O O
activated O O
cell O O
sorter O O
, O O
immunostaining O O
. O O

Cell O O
proliferation O O
response O O
radiation O O
measured O O
WST-8 O O
assay O O
. O O

Incidence O O
human B-virus B-virus
papillomavirus E-virus E-virus
( O O
HPV B-virus B-virus
) O O
#NAME? O O
head O O
neck O O
squamous O O
cell O O
carcinoma O O
( O O
HNSCC O O
) O O
rising O O
several O O
countries O O
. O O

Intriguingly O O
, O O
large O O
variations O O
HPV16 B-virus B-virus
viral O O
load O O
different O O
proportions O O
physical O O
viral O O
status O O
among O O
HNSCC O O
reported O O
. O O

We O O
analysed O O
fresh O O
biopsies O O
275 O O
HNSCC O O
patients O O
South O O
Swedish O O
Health O O
Care O O
Region O O
HPV B-virus B-virus
types O O
modified O O
general O O
primer O O
PCR O O
Luminex O O
. O O

Seventy-eight O O
HPV16-positive B-virus B-virus
HNSCC O O
cases O O
investigated O O
viral O O
DNA O O
load O O
physical O O
status O O
using O O
quantitative O O
PCR O O
HPV B-virus B-virus
E2 O O
E7 O O
genes O O
. O O

Presence O O
intact O O
E2 O O
gene O O
, O O
surrogate O O
marker O O
episomal O O
HPV B-virus B-virus
, O O
investigated O O
conventional O O
PCR O O
. O O

Fifteen O O
different O O
HPV B-virus B-virus
types O O
detected O O
HNSCC O O
cases O O
HPV16 B-virus B-virus
present O O
74 O O
% O O
HPV-positive B-virus B-virus
cases O O
. O O

HPV B-virus B-virus
detected O O
65 O O
% O O
( O O
92/141 O O
) O O
11 O O
% O O
( O O
15/134 O O
) O O
oropharyngeal O O
non-oropharyngeal O O
carcinomas O O
, O O
respectively O O
( O O
P O O
< O O
0.0001 O O
) O O
. O O

HPV B-virus B-virus
detected O O
73 O O
% O O
( O O
75/103 O B-virus
) O O
tonsillar O O
carcinomas O O
. O O

The O O
median O O
load O O
HPV16 B-virus B-virus
13 O O
copies O O
cell-1 O O
( O O
range O O
0.003-1080 O O
) O O
. O O

Among O O
HPV16-positive B-virus O
patients O O
oropharyngeal O O
carcinoma O O
, O O
metastases O O
regional O O
lymph O O
nodes O O
observed O O
100 O O
% O O
( O O
17/17 O O
) O O
68 O O
% O O
( O O
40/58 O O
) O O
< O O
1 O O
HPV16 O B-virus
copy O O
cell-1 O O
> O O
1 O O
HPV16 B-virus B-virus
copy O O
cell-1 O O
, O O
respectively O O
( O O
P=0.007 O O
) O O
. O O

Among O O
HPV16 B-virus B-virus
cases O O
, O O
purely O O
integrated O O
HPV16 B-virus B-virus
found O O
6 O O
% O O
, O O
whereas O O
entirely O O
episomal O B-virus
mixed O O
virus B-virus B-virus
detected O O
51 O O
42 O O
% O O
cases O O
, O O
respectively O O
. O O

Conclusively O O
, O O
HPV16 B-virus B-virus
viral O O
DNA O O
load O O
demonstrated O O
large O O
diversity O O
among O O
HNSCCs O O
. O O

Although O O
integration O O
HPV16 B-virus B-virus
common O O
( O O
48 O O
% O O
) O O
, O O
episomal O B-virus
HPV16 B-virus B-virus
salient O O
( O O
93 O O
% O O
) O O
among O O
HPV16 B-virus B-virus
HNSCCs O O
. O O

In O O
addition O O
, O O
low O O
amount O O
HPV16 O B-virus
associated O O
lymph O O
node O O
metastases O O
among O O
oropharyngeal O O
carcinomas O O
. O O

This O O
retrospective O O
study O O
, O O
clinical O O
data O O
collected O O
82 O O
patients O O
. O O

Human B-virus B-virus
papilomavirus E-virus E-virus
detection O O
conducted O O
specimens O O
oral O O
cavity O O
oropharynx O O
carcinomas O O
included O O
paraffin O O
blocks O O
. O O

Patients O O
assisted O O
cancer O O
reference O O
center O O
, O O
central O O
region O O
Brazil O O
, O O
2005 O O
2007 O O
. O O

Polymerase O O
chain O O
reaction O O
used O O
detection O O
genotyping O O
human B-virus O
papilomavirus E-virus E-virus
. O O

There O O
government O O
licensed O O
viral O O
gene O O
therapy O O
products O O
currently O O
use O O
head O O
neck O O
cancer O O
, O O
utilised O O
conjunction O O
established O O
treatment O O
modalities O O
. O O

The O O
viruses B-virus B-virus
target O O
tumour-associated O O
genes O O
, O O
first O O
licensed B-virus O
virus E-virus B-virus
replacing O O
p53 O O
gene O O
function O O
, O O
frequently O O
lost O O
tumourigenesis O O
. O O

Oncolytic B-virus B-virus
viruses E-virus E-virus
selectively O O
destroy O O
cancer O O
cells O O
viral O O
replication O O
armed O O
therapeutic O O
transgenes O O
. O O

Smoking O O
human B-virus B-virus
papillomavirus E-virus E-virus
( O O
HPV B-virus B-virus
) O O
distinct O O
risk O O
factors O O
head O O
neck O O
cancer O O
, O O
nature O O
interaction O O
2 O O
risk O O
factors O O
development O O
head O O
neck O O
cancer O O
remains O O
unclear O O
. O O

The O O
purpose O O
review O O
determine O O
potential O O
effect O O
smoking O O
causation O O
HPV-related B-virus B-virus
head O O
neck O O
carcinoma O O
. O O

High-risk O B-virus
human B-virus I-virus
papillomavirus E-virus E-virus
( O O
HPV B-virus B-virus
) O O
recognised O O
principal O O
cause O O
increasing O O
incidence O O
rates O O
oropharyngeal O O
squamous O O
cell O O
carcinoma O O
( O O
OPSCC O O
) O O
parts O O
world O O
. O O

The O O
primary O O
risk O O
factor O O
developing O O
HPV-related B-virus B-virus
OPSCC O B-virus
oral O O
HPV-infection B-virus O
majority O O
oral O O
HPV-infections B-virus O
acquired O O
oral O O
sex O O
. O O

Progression O O
OPSCC O O
includes O O
persistent O O
infection O O
evasion O O
immune O O
response O O
microenvironment O O
, O O
activation O O
viral O O
early O O
genes O O
( O O
E6 O O
, O O
E7 O O
) O O
basal O O
epithelial O O
cells O O
, O O
deregulation O O
cell O O
cycle O O
accumulation O O
chromosomal O O
instability O O
. O O

Patients O O
affected O O
HPV-related B-virus B-virus
OPSCC O B-virus
tend O O
younger O O
better O O
outcomes O O
. O O

This O O
observation O O
lead O O
current O O
research O O
evaluate O O
treatment O O
de-escalation O O
options O O
reduce O O
long-term O O
associated O O
morbidity O O
. O O

Moreover O O
, O O
different O O
molecular O O
profile O O
HPV-related B-virus B-virus
OPSCC O B-virus
described O O
, O O
opening O O
new O O
options O O
targeted O O
therapy O O
immunotherapy O O
approaches O O
. O O

This O O
paper O O
comprehensively O O
reviews O O
accumulated O O
knowledge O O
regarding O O
role O O
HPV B-virus B-virus
OPSCC O O
spanning O O
infection O O
cancer O O
development O O
, O O
including O O
clinical O O
diagnosis O O
, O O
management O O
preventive O O
strategies O O
. O O

Low-intensity O O
ultrasound O O
useful O O
method O O
enhance O O
delivery O O
drugs O O
target O O
cells O O
via O O
range O O
mechanisms O O
including O O
transient O O
formation O O
micropores O O
cell O O
membrane O O
, O O
process O O
known O O
sonoporation O O
. O O

The O O
effect O O
ultrasound O O
oncolytic O B-virus
herpes B-virus I-virus
simplex I-virus I-virus
virus I-virus E-virus
type-1 E-virus E-virus
( O O
HSV-1 B-virus B-virus
) O O
infection O O
oral O O
squamous O O
cell O O
carcinoma O O
( O O
SCC O O
) O O
examined O O
. O O

Human O O
SCC O O
cell O O
line O O
SAS O O
oncolytic O O
HSV-1 B-virus B-virus
RH2 O O
, O O
deficient O O
neurovirulent O O
款134.5 O O
gene O O
exhibited O O
cell O O
fusion O O
actions O O
, O O
used O O
. O O

Cells O O
grown O O
multi-well O O
plates O O
infected O O
HSV-1 B-virus B-virus
exposed O O
ultrasound O O
presence O O
absence O O
microbubbles O O
adsorption O O
period O O
. O O

The O O
number O O
plaques O O
significantly O O
greater O O
untreated O O
control O O
. O O

SAS O O
cells O O
inoculated O O
subcutaneously O O
nude O O
mice O O
tumors O O
produced O O
. O O

Tumors O O
injected O O
HSV-1 B-virus B-virus
RH2 O O
without O O
microbubbles O O
exposed O O
ultrasound O O
covering O O
skin O O
. O O

The O O
amount O O
virus B-virus B-virus
tumor O O
tissues O O
3 O O
days O O
injection O O
higher O O
tumors O O
treated O O
HSV-1 B-virus B-virus
RH2 O O
ultrasound O O
tumors O O
treated O O
RH2 O O
. O O

The O O
expression O O
HSV-1 B-virus B-virus
antigen O O
also O O
increased O O
ultrasound O O
microbubbles O O
. O O

Tumor O O
growth O O
suppressed O O
HSV-1 B-virus B-virus
RH2 O O
combination O O
ultrasound O O
, O O
especially O O
microbubbles O O
. O O

These O O
results O O
indicated O O
ultrasound O O
increased O O
efficiency O O
HSV-1 B-virus B-virus
infection O O
SAS O O
cells O O
nude O O
mouse O O
tumors O O
. O O

This O O
method O O
potentially O O
useful O O
enhance O O
antitumor O O
effects O O
oncolytic O O
HSV-1 B-virus B-virus
head O O
neck O O
cancer O O
treatment O O
. O O

The O O
goal O O
determine O O
prevalence O O
high-risk B-virus B-virus
HPV16 E-virus E-virus
using O O
saliva O O
screening O O
population O O
Detroit O O
, O O
Michigan O O
. O O

Human B-virus O
papillomavirus-related E-virus E-virus
oropharyngeal O O
squamous O O
cell O O
carcinoma O O
associated O O
cystic O O
lymph O O
nodes O O
CT O O
favorable O O
prognosis O O
. O O

A O O
subset O O
patients O O
aggressive O O
disease O O
experience O O
treatment O O
failure O O
. O O

Our O O
aim O O
determine O O
whether O O
extent O O
cystic O O
lymph O O
node O O
burden O O
staging O O
CT O O
serve O O
imaging O O
biomarker O O
predict O O
treatment O O
failure O O
human B-virus O
papillomavirus-related E-virus E-virus
oropharyngeal O O
squamous O O
cell O O
carcinoma O O
. O O

Background O O
: O O
Head O O
Neck O O
Squamous O O
Cell O O
Carcinomas O O
( O O
HNSCC O O
) O O
sixth O O
common O O
cancer O O
globally O O
. O O

In O O
India O O
, O O
average O O
25-30 O O
% O O
cancer O O
cases O O
affect O O
head O O
neck O O
. O O

The O O
etiological O O
factors O O
associated O O
HNSCC O O
tobacco O O
, O O
alcohol O O
environmental O O
carcinogens O O
. O O

However O O
cases O O
, O O
obvious O O
risk O O
factors O O
involved O O
. O O

In O O
western O O
counties O O
, O O
many O O
reports O O
human B-virus B-virus
papilloma I-virus I-virus
virus E-virus E-virus
( O O
HPV B-virus B-virus
) O O
association O O
HNSCC O O
. O O

Hence O O
, O O
conducted O O
study O O
determine O O
role O O
HPV B-virus B-virus
infection O O
risk O O
factors O O
among O O
patients O O
HNSCC O O
. O O

Materials O O
Methods O O
: O O
A O O
prospective O O
, O O
cross-sectional O O
study O O
conducted O O
tertiary O O
referral O O
centre O O
January O O
2014 O O
March O O
2016 O O
. O O

88 O O
patients O O
enrolled O O
study O O
. O O

Socio- O O
demographic O O
, O O
behavioural O O
data O O
, O O
site O O
subsite O O
involvement O O
, O O
histopathology O O
, O O
staging O O
treatment O O
documented O O
. O O

Polymerase O O
chain O O
reaction O O
( O O
PCR O O
) O O
performed O O
detect O O
presence O O
HPV B-virus B-virus
DNA O O
using O O
consensus O O
primers O O
MY O O
9月11日 O O
GP5+/GP6+ O O
samples O O
subjected O O
PCR O O
detecting O O
HPV B-virus B-virus
type O O
16 O O
18 O O
. O O

Results O O
: O O
The O O
study O O
included O O
88 O O
participants O O
HNSCC O O
. O O

57 O O
oral O O
oropharyngeal O O
squamous O O
cell O O
carcinoma O O
, O O
11 O O
laryngeal O O
malignancy O O
20 O O
involving O O
hypopharynx O O
. O O

Among O O
participants O O
buccal O O
mucosa O O
( O O
n=22 O O
) O O
common O O
subsite O O
involved O O
, O O
majority O O
( O O
50 O O
% O O
) O O
moderately O O
differentiated O O
squamous O O
cell O O
carcinoma O O
53.4 O O
% O O
presented O O
stage O O
IV O O
. O O

2 O O
( O O
2.6 O O
% O O
) O O
cases O O
positive O O
HPV B-virus B-virus
consensus O O
positive O O
HPV B-virus B-virus
16 O O
, O O
one O O
case O O
larynx O O
hypopharynx O O
. O O

There O O
statistical O O
significance O O
association O O
betel O O
nut O O
chewing O O
, O O
cigarette O O
smoking O O
alcohol O O
intake O O
risk O O
factors O O
carcinogenesis O O
HNSCC O O
. O O

Conclusion O O
: O O
In O O
setting O O
South O O
India O O
, O O
HPV B-virus B-virus
play O O
major O O
role O O
carcinogenesis O O
HNSCC O O
betel O O
nut O O
chewing O O
, O O
tobacco O O
exposure O O
alcohol O O
consumption O O
remain O O
major O O
risk O O
factors O O
HNSCC O O
. O O

Human B-virus B-virus
papillomavirus E-virus E-virus
( O O
HPV B-virus B-virus
) O O
major O O
causative O O
agent O O
cervical O O
cancers O O
. O O

Over O O
past O O
several O O
decades O O
, O O
increasing O O
number O O
studies O O
established O O
strong O O
association O O
HPV B-virus B-virus
subset O O
head O O
neck O O
squamous O O
cell O O
carcinomas O O
( O O
HNSCCs O O
) O O
. O O

In O O
present O O
study O O
, O O
reviewed O O
evidence O O
, O O
including O O
epidemiology O O
, O O
carcinogens O O
, O O
diagnosis O O
, O O
treatment O O
, O O
prognosis O O
, O O
showing O O
HPV-positive B-virus B-virus
HNSCCs O B-virus
exhibit O O
variety O O
distinct O O
characteristics O O
understanding O O
tumor O O
biology O O
improving O O
cancer O O
treatment O O
. O O

The O O
interesting O O
history O O
papillomavirus B-virus B-virus
( O O
PV B-virus O
) O O
research O O
reviewed O O
. O O

The O O
history O O
human B-virus B-virus
papillomavirus E-virus E-virus
( O O
HPV B-virus B-virus
) O O
head O O
neck O O
region O O
starts O O
1901 O O
contagious O O
transmission O O
warty O O
lesions O O
mouth O O
via O O
oral O O
sex O O
described O O
, O O
although O O
confirmation O O
viral O O
etiology O O
wait O O
1907 O O
. O O

Ullman O O
first O O
associate O O
human B-virus B-virus
wart I-virus I-virus
virus E-virus E-virus
laryngeal O O
warts O O
. O O

Parsons O B-virus
Kidd O O
described O O
natural O O
history O O
oral O O
PV B-virus O
infections O O
rabbits O O
already O O
1942 O O
, O O
findings O O
corroborated O O
humans O O
recently O O
. O O

Koilocytotic O O
atypia O O
described O O
Koss O O
Durfee O O
1956 O O
recognized O O
sign O O
HPV B-virus B-virus
infection O O
cervical O O
precancer O O
lesions O O
1976-1977 O O
( O O
Meisels O O
Fortin O O
; O O
Purola O O
Savia O O
) O O
. O O

This O O
prompted O O
systematic O O
surveys O O
head O O
neck O O
lesions O O
detection O O
koilocytosis O O
since O O
late O O
1970s O O
, O O
authors O O
communication O O
first O O
propose O O
HPV B-virus B-virus
involvement O O
subgroup O O
head O O
neck O O
cancers O O
. O O

Brandsma O O
Abramson O O
demonstrated O O
HPV16 B-virus B-virus
DNA O O
tonsillar O O
SCCs O O
1989 O O
. O O

Since O O
early O O
2000s O O
, O O
HPV B-virus B-virus
research O O
head O O
neck O O
squamous O O
cell O O
carcinomas O O
( O O
HNSCC O O
) O O
made O O
impressive O O
progress O O
, O O
confirming O O
specific O O
anatomic O O
site O O
plays O O
key O O
role O O
determining O O
susceptibility O O
HPV B-virus B-virus
infection O O
. O O

The O O
likely O O
cancer O O
sites O O
associated O O
HPV B-virus B-virus
base O O
tongue O O
palatine O O
tonsils O O
, O O
followed O O
oral O O
cavity O O
, O O
larynx O O
, O O
sinonasal O O
mucosa O O
. O O

There O O
substantial O O
geographic O O
variation O O
HPV B-virus B-virus
association O O
HNSCC O O
. O O

Patients O O
HPV-associated B-virus B-virus
HNSCC O O
younger O O
, O O
survival O O
better O O
absence O O
HPV B-virus B-virus
. O O

Despite O O
considerable O O
advances O O
field O O
last O O
40 O O
years O O
, O O
research O O
needed O O
improve O O
overall O O
efficacy O O
viruses B-virus B-virus
allow O O
widespread O O
utilisation O O
management O O
head O O
neck O O
cancer O O
. O O

All O O
HPV-positive B-virus B-virus
cell O O
lines O O
expressed O O
alternate O O
HPVE6/E7 B-virus O
splicing O O
indicative O O
active O O
viral O O
oncogenesis O O
. O O

HPV B-virus B-virus
integration O O
occurred O O
within O O
cancer-related O O
genes O O
TP63 O O
, O O
DCC O O
, O O
JAK1 O O
, O O
TERT O O
, O O
ATR O B-virus
, O O
ETV6 O O
, O O
PGR O O
, O O
PTPRN2 O B-virus
, O O
TMEM237 O O
8 O O
head O O
neck O O
squamous O O
cell O O
carcinoma O O
( O O
HNSCC O O
) O O
lines O O
UM-SCC-105 O O
UM-GCC-1 O O
intergenic O O
integration O O
. O O

A O O
total O O
61 O O
pathological O O
specimens O O
examined O O
: O O
39.5 O O
% O O
( O O
15/38 O O
) O O
pleomorphic O O
adenomas O O
, O O
33.3 O O
% O O
( O O
3月9日 O B-virus
) O O
Warthin O O
's O O
tumours O O
, O O
33.3 O O
% O O
( O O
one O O
3 O O
) O O
mucoepidermoid O O
carcinomas O O
, O O
25 O O
% O O
( O O
one O O
4 O O
) O O
benign O O
lymphoepithelial O O
lesions O O
positive O O
high-risk O B-virus
HPV B-virus E-virus
16/18 E-virus O
. O O

Only O O
two O O
Warthin O O
's O O
tumours O O
positive O O
EBV B-virus B-virus
. O O

Although O O
Japan O O
non-endemic O O
area O O
nasopharyngeal O O
carcinoma O O
( O O
NPC O O
) O O
, O O
proportion O O
WHO O O
type O O
I O O
NPC O O
Japan O O
different O O
non-endemic O O
areas O O
North O O
America O O
Europe O O
. O O

Recently O O
, O O
said O O
Epstein-Barr B-virus B-virus
virus E-virus E-virus
( O O
EBV B-virus B-virus
) O O
also O O
human B-virus B-virus
papillomavirus E-virus E-virus
( O O
HPV B-virus B-virus
) O O
influence O O
NPC O O
non-endemic O O
areas O O
. O O

The O O
aim O O
study O O
clarify O O
influence O O
HPV B-virus B-virus
NPC O O
Japan O O
. O O

Reduced O O
engraftment O O
HPV B-virus B-virus
+ E-virus E-virus
tumors O O
lacking O O
PNI O O
likely O O
results O O
selection O O
biases O O
HNSCC O O
PDX O O
models O O
. O O

Formation O O
EBV B-virus B-virus
+ E-virus O
lymphomas O O
NSG O O
mice O O
reduces O O
generation O O
HPV B-virus B-virus
+ E-virus O
models O O
must O O
ruled O O
long-term O O
use O O
PDXs O O
. O O

Nevertheless O O
, O O
retention O O
distinctive O O
pathologic O O
traits O O
viral O O
oncogene O O
expression O O
HPV B-virus B-virus
+ E-virus O
PDXs O O
provides O O
viable O O
vivo O O
platform O O
basic O O
translational O O
studies O O
well O O
resource O O
generating O O
advanced O O
vitro O O
models O O
. O O

E6/E7 O O
alternate O O
transcripts O O
assessed O O
reverse O O
transcriptase-polymerase O O
chain O O
reaction O O
( O O
RT-PCR O O
) O O
. O O

Detection O O
integrated O O
papillomavirus B-virus B-virus
sequences O O
( O O
DIPS-PCR O O
) O O
sequencing O O
identified O O
viral O O
insertion O O
sites O O
affected O O
host O O
genes O O
. O O

Cellular O O
gene O O
expression O O
assessed O O
across O O
viral O O
integration O O
sites O O
. O O

Increased O O
awareness O O
human B-virus B-virus
papillomavirus E-virus E-virus
( O O
HPV B-virus B-virus
) O O
etiological O O
cause O O
head O O
neck O O
squamous O O
cell O O
carcinoma O O
increased O O
interest O O
analysis O O
distinct O O
oral O O
sub-sites O O
. O O

It O O
currently O O
debate O O
, O O
whether O O
HPV B-virus B-virus
plays O O
role O O
development O O
squamous O O
cell O O
carcinoma O O
oral O O
cavity O O
( O O
OSCC O O
) O O
. O O

The O O
weakness O O
published O O
studies O O
lack O O
performing O O
different O O
HPV B-virus B-virus
detection O O
tests O O
combined O O
analysis O O
biological O O
activity O O
virus B-virus B-virus
. O O

In O O
addition O O
, O O
different O O
sub-sites O O
oral O O
cavity O O
combined O O
single O O
entity O O
, O O
retrospectively O O
leads O O
highly O O
heterogeneous O O
basis O O
data O O
. O O

In O O
review O O
mainly O O
discuss O O
unclear O O
role O O
HPV B-virus B-virus
OSCC O O
development O O
. O O

Case O O
report O O
literature O O
review O O
. O O

